United States Patent 7,867,996: Ivabradine Hydrochloride Gamma-Crystalline Form, Claim Scope and Patent Landscape
U.S. Patent 7,867,996 protects a specific gamma crystalline polymorph of ivabradine hydrochloride, identified by powder X-ray diffraction peaks. The patent also covers solid compositions containing that polymorph and its use to treat angina pectoris, myocardial infarction, and heart failure. Its commercial importance is concentrated in polymorph control and drug-substance manufacturing, not in the underlying ivabradine molecule.
The patent is associated with Les Laboratoires Servier and the U.S. Corlanor product. Public Orange Book records report an expiration date of April 8, 2025. On that basis, the patent no longer blocks a post-expiration generic launch, although other patents, regulatory requirements, and manufacturing considerations may still affect market entry.[1][2]
What does U.S. Patent 7,867,996 protect?
The patent protects the gamma crystalline form of ivabradine hydrochloride, rather than ivabradine hydrochloride generally.
| Item |
Analysis |
| Patent |
U.S. Patent 7,867,996 |
| Title |
Gamma crystalline form of ivabradine hydrochloride |
| Patent holder |
Les Laboratoires Servier |
| Active ingredient |
Ivabradine hydrochloride |
| Technology |
Solid-state polymorph |
| Dosage-form coverage |
Solid pharmaceutical compositions |
| Therapeutic coverage |
Angina pectoris, myocardial infarction, and heart failure |
| Key analytical method |
Powder X-ray diffraction |
| Reported expiration |
April 8, 2025 |
| FDA product most closely associated |
Corlanor, ivabradine hydrochloride tablets |
| Regulatory route for competitors |
ANDA for a small-molecule generic |
The patent does not claim the ivabradine molecule broadly. The foundational compound patent for ivabradine was separate and expired earlier. Patent 7,867,996 is a later solid-state patent directed to a particular crystalline arrangement of the hydrochloride salt.
What are the scope and limitations of claims 1 and 2?
Claims 1 and 2 are product-by-process-independent product claims defined by XRPD characteristics. They do not require a particular manufacturing process. A product can infringe if it has the claimed gamma crystalline form, even if it was produced by a different process.
Claim 1
Claim 1 covers a gamma crystalline form of ivabradine hydrochloride having XRPD peaks at:
- 4.2 degrees 2-theta; and
- 13.4 degrees 2-theta.
The claim is relatively broad in analytical terms because it identifies only two peaks. It does not expressly require the complete diffraction pattern or the additional peaks recited in claim 2.
The principal infringement issue would be whether a competing ivabradine hydrochloride batch exhibits both required peaks under comparable XRPD testing conditions. A patent owner would normally also need to establish that the material is the claimed gamma form of ivabradine hydrochloride, not a different substance that happens to produce peaks at similar angles.
Claim 2
Claim 2 covers the gamma crystalline form having peaks at:
- 4.2 degrees 2-theta;
- 13.4 degrees 2-theta;
- 21.1 degrees 2-theta;
- 24.2 degrees 2-theta;
- 24.5 degrees 2-theta; and
- 26.4 degrees 2-theta.
Claim 2 is narrower than claim 1 because it requires the additional four peaks. It provides a more specific fingerprint for the polymorph and may be easier to defend against an argument that the two peaks in claim 1 are insufficiently distinctive.
The claims do not state peak intensities, relative intensities, instrumental settings, radiation source, sample preparation, or an explicit tolerance for peak position. Those omissions can create claim-construction and reproducibility issues. In practice, XRPD peak positions are evaluated with reasonable analytical tolerance because instrument calibration, sample orientation, crystallite size, and test conditions can shift measured values.
Claim comparison
| Claim |
Protected subject matter |
Relative breadth |
Main proof issue |
| 1 |
Gamma ivabradine hydrochloride with peaks at 4.2 and 13.4 degrees 2-theta |
Broader |
Whether the two-peak limitation identifies the claimed polymorph |
| 2 |
Gamma form with six specified peaks |
Narrower |
Whether all six peaks are present within accepted analytical tolerance |
What do claims 3 and 5 protect?
Claims 3 and 5 cover solid pharmaceutical compositions containing the gamma crystalline form with one or more pharmaceutically acceptable, inert, non-toxic carriers.
Claim 3 incorporates the gamma form of claim 1. Claim 5 incorporates the more narrowly defined gamma form of claim 2.
These claims are composition claims, but they are not limited to a particular:
- tablet strength;
- excipient;
- dissolution profile;
- release mechanism;
- particle-size distribution;
- manufacturing process;
- coating;
- packaging system; or
- commercial formulation.
The word “comprising” preserves open-ended scope. A composition containing the claimed gamma form and additional active or inactive ingredients can fall within the claim, assuming the gamma form is present in the composition.
The commercial reach of these claims depends on whether the marketed or generic product contains the protected polymorph. A tablet manufacturer could attempt to use a different ivabradine hydrochloride polymorph or an amorphous form, but it would need to demonstrate adequate stability, dissolution, bioequivalence, and manufacturing consistency.
What do claims 4 and 6 protect?
Claims 4 and 6 are method-of-treatment claims. They cover administering a therapeutically effective amount of the gamma crystalline form to a human to treat:
- angina pectoris;
- myocardial infarction; or
- heart failure.
Claim 4 refers to the form in claim 1. Claim 6 refers to the form in claim 2.
These claims are narrower than a broad ivabradine treatment claim because the administered active ingredient must be the claimed crystalline form. They also require human treatment and a therapeutic purpose. They do not specify:
- dose;
- dosing frequency;
- treatment duration;
- patient age;
- New York Heart Association class;
- concomitant therapy;
- route of administration; or
- tablet strength.
The inclusion of “myocardial infarct” is broader or differently framed than the currently approved U.S. Corlanor indication. The FDA-approved Corlanor label covers treatment of stable symptomatic heart failure in adult patients with stable, symptomatic heart failure and a reduced ejection fraction, and reduction of hospitalization risk for pediatric patients with stable heart failure due to dilated cardiomyopathy.[3] FDA labeling should be reviewed separately from the broader language of the patent claims.
When did U.S. Patent 7,867,996 expire?
Public Orange Book information reports an expiration date of April 8, 2025.[1] The patent therefore no longer provides an enforceable exclusionary right after that date, absent a legally effective term adjustment, restoration, or other specific term extension.
The patent’s practical exclusivity period was shorter than the life of ivabradine’s original compound protection because polymorph protection was obtained later. This is typical of pharmaceutical solid-state portfolios: the active ingredient may lose basic compound protection while a selected crystalline form remains relevant to commercial supply and regulatory filings.
| Milestone |
Significance |
| Priority period in the mid-2000s |
Servier’s polymorph strategy was established after the underlying ivabradine compound |
| Patent grant |
U.S. 7,867,996 issued in 2011 |
| Corlanor U.S. approval |
FDA approved Corlanor in April 2015 |
| Reported patent expiration |
April 8, 2025 |
| Post-expiration position |
Polymorph patent no longer independently blocks generic entry |
What is the Orange Book status of ivabradine and U.S. Patent 7,867,996?
Corlanor is an FDA-approved small-molecule drug marketed as ivabradine hydrochloride tablets. The NDA is 206143, held by Amgen.[3]
Patent 7,867,996 has been associated with the U.S. ivabradine product in Orange Book records. Its listing is commercially relevant because an ANDA applicant referencing Corlanor would have had to address the patent through one of the statutory certification pathways under the Hatch-Waxman Act.
The key post-expiration effect is that the patent no longer supports a current Paragraph IV enforcement strategy based solely on this patent. A generic applicant filing after expiration generally would not need to litigate the patent as an unexpired barrier, although it would still need to satisfy FDA requirements for pharmaceutical equivalence, bioequivalence, labeling, quality, and manufacturing controls.[1][4]
Which companies challenged the ivabradine patent?
The available record does not establish a current, active Paragraph IV litigation campaign directed specifically at U.S. Patent 7,867,996. No active challenge should be inferred solely from the existence of an Orange Book listing.
A Paragraph IV certification would have required an ANDA applicant to assert that the patent was invalid, unenforceable, or not infringed. A generic applicant could also have used a Paragraph III certification, agreeing to await patent expiration. Because the reported expiration date has passed, the commercial value of a new Paragraph IV challenge to this patent is limited.
The absence of a confirmed active case does not eliminate historical litigation risk. Relevant searches should distinguish among:
- patent lawsuits naming U.S. 7,867,996;
- cases involving other ivabradine patents;
- declaratory-judgment actions;
- ANDA settlements; and
- disputes over products that contain a different polymorph.
How strong is the patent estate for the gamma form?
The patent was technically meaningful before expiration but had a defined vulnerability profile.
Strengths
The patent had several structural advantages:
- It claimed the drug substance in a specific crystalline form.
- It did not depend on a manufacturing process.
- XRPD provides a reproducible analytical tool for identifying solid forms.
- Composition claims extended the protection into tablets and other solid products.
- The method claims linked the form to clinically relevant uses.
- A generic product using the same gamma form could face both product and composition claim issues.
Vulnerabilities
The main vulnerabilities were:
- Claim 1 relies on only two XRPD peaks.
- Claim 2 requires a specific pattern but may be vulnerable to analytical disagreement over tolerances.
- The claims do not expressly define peak intensity or a complete XRPD profile.
- Prior-art crystalline forms, preparation methods, and salt forms could support anticipation or obviousness arguments.
- Composition claims are broad but may be difficult to enforce if the generic product uses another polymorph.
- Method claims may be limited by the approved indication, physician conduct, labeling, and induced-infringement evidence.
- Expiration eliminated the patent’s forward-looking blocking power.
For validity analysis, the most important technical evidence would be earlier ivabradine hydrochloride solid forms, XRPD data, crystallization conditions, and evidence that the gamma form had unexpected stability, purity, hygroscopicity, bioavailability, or manufacturing advantages.
What manufacturing and intellectual-property barriers remain?
The gamma-form claims create a manufacturing-control issue even after patent expiration. A generic producer must maintain polymorph identity across:
- crystallization;
- drying;
- milling;
- storage;
- blending;
- compression;
- coating; and
- shipment.
Polymorph conversion can occur through moisture, heat, solvent exposure, mechanical stress, or seeding by another crystalline form. A producer that intentionally selects a non-gamma form may avoid these claims, but it must establish that the alternate form is suitable for the proposed product.
The patent itself does not disclose a monopoly over every method of making ivabradine hydrochloride. Manufacturing barriers may instead arise from process know-how, scale-up experience, impurity control, crystallization kinetics, and regulatory documentation.
How does this patent compare with the broader ivabradine patent estate?
| Patent category |
Typical subject matter |
Relevance after 2025 |
| Compound patent |
Ivabradine molecule and salts |
Basic protection expired earlier |
| Polymorph patent |
Gamma crystalline ivabradine hydrochloride |
U.S. 7,867,996; reported expiration April 8, 2025 |
| Formulation patents |
Tablets, excipients, release or stability characteristics |
Must be reviewed individually |
| Method-of-use patents |
Heart failure, angina, or cardiovascular treatment |
Scope depends on claims, listing, and expiration |
| Manufacturing patents |
Crystallization, purification, or solid-form preparation |
Can create process-specific barriers |
| Regulatory exclusivity |
NDA, pediatric, or other FDA exclusivity |
Separate from patent term |
U.S. 7,867,996 should therefore be treated as one layer of the ivabradine portfolio, not as a complete statement of all remaining exclusivity. A freedom-to-operate review must examine later formulation, process, and use patents and confirm their current legal status.
What generic launch risks exist for ivabradine?
The direct risk from U.S. Patent 7,867,996 is now substantially reduced because the reported patent term has ended. Generic entry risks shift to four areas:
- Other unexpired Orange Book-listed patents.
- Non-listed process or formulation patents.
- FDA requirements for demonstrating pharmaceutical equivalence and bioequivalence.
- Manufacturing consistency for the selected ivabradine solid form.
A generic using the same gamma form would have faced the highest risk before April 8, 2025. A generic using a different form could have reduced polymorph infringement risk but incurred greater development and regulatory risk.
Ivabradine is a small molecule, so biosimilar litigation is not applicable. Competitors would use the ANDA pathway rather than the abbreviated pathway for biologics.
What licensing deals affect ivabradine commercialization?
Servier developed ivabradine and entered into a U.S. commercialization arrangement with Amgen. Amgen obtained U.S. rights to commercialize ivabradine, which was subsequently marketed as Corlanor.[5]
The commercial arrangement does not by itself establish ownership of every patent in the ivabradine portfolio. Patent ownership, licensing rights, enforcement authority, and royalty obligations must be reviewed from the applicable assignment and license records. The relevant distinction is:
- Servier: originator and principal historical patent holder;
- Amgen: U.S. NDA holder and commercial partner for Corlanor;
- generic companies: potential ANDA applicants and post-expiration competitors.
Key Takeaways
- U.S. Patent 7,867,996 protects the gamma crystalline form of ivabradine hydrochloride.
- Claims 1 and 2 are XRPD-defined product claims, with claim 1 broader and claim 2 more specific.
- Claims 3 and 5 extend protection to solid pharmaceutical compositions containing the gamma form.
- Claims 4 and 6 cover human treatment of specified cardiovascular conditions using the gamma form.
- The patent does not broadly protect ivabradine or every ivabradine hydrochloride formulation.
- Public Orange Book information reports expiration on April 8, 2025.
- The patent is no longer an independent post-expiration barrier to an ivabradine ANDA.
- No current Paragraph IV litigation should be inferred without a case-specific docket and ANDA record.
- Polymorph selection, manufacturing reproducibility, and other formulation or process patents remain relevant to generic development.
- Ivabradine is a small molecule; biosimilar risk does not apply.
FAQs About U.S. Patent 7,867,996
Does U.S. Patent 7,867,996 cover Corlanor itself?
It covers Corlanor only to the extent that the product contains the claimed gamma crystalline form of ivabradine hydrochloride. It does not claim all ivabradine products regardless of solid form.
Can a generic avoid the patent by using amorphous ivabradine hydrochloride?
Before expiration, an amorphous product could potentially avoid infringement of the crystalline-form claims, but it would still require separate evaluation for other patents and FDA approval requirements. After the reported expiration date, this patent alone does not prevent use of the gamma form.
Are the XRPD peaks in claim 1 enough to identify the gamma form?
They are the express limitations of claim 1, but infringement and validity analysis would also consider the identity of the material, testing tolerances, peak reproducibility, and the patent specification.
Does the patent cover injectable ivabradine?
The claims expressly focus on a crystalline form, solid pharmaceutical compositions, and administration to humans. The composition claims do not expressly require an injectable dosage form. A separate analysis would be required for a liquid or parenteral product.
Is ivabradine subject to biosimilar competition?
No. Ivabradine is a chemically synthesized small molecule. Competition proceeds through the generic-drug framework, principally an ANDA, rather than the biosimilar pathway.
References
- U.S. Food and Drug Administration. (2025). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/
- United States Patent and Trademark Office. (2011). U.S. Patent No. 7,867,996: Gamma crystalline form of ivabradine hydrochloride. https://patents.google.com/patent/US7867996B2/en
- U.S. Food and Drug Administration. (2015). Corlanor (ivabradine hydrochloride) prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/
- U.S. Food and Drug Administration. (2024). Abbreviated new drug application regulations and patent certifications. https://www.fda.gov/drugs/
- Amgen Inc. (2013). Amgen and Servier enter agreement for ivabradine in the United States. Amgen corporate communications. https://www.amgen.com/newsroom/press-releases/
